Condition: Primary/Secondary Prevention · High Risk for Febrile Neutropenia of Chemotherapy Regimens · Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia · Sponsor: Henan Cancer Hospital
Efbemalenograstim alfa for primary/secondary prevention in patients with solid tumors at high risk for febrile neutropenia (FN) or Intermediate risk of chemotherapy regimens associated with other risk factors in FN
This description comes directly from the study's public registry record.
Zhenzhen Liu, Dr. · 0371-65588251 · liuzhenzhen73@126.com
Always discuss trial participation with your own doctor first.
| The Henan cancer hospital | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07187908